Table 1 Patient characteristics

From: A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

Gender

 

 Male

15

 Female

6

Median Age (range) years

62 (39–73)

Performance status

 

 0

2

 1

17

 2

2

Site of primary disease

 

 Colorectal

9

 Ovarian

2

 Unknown primary

2

 Lung

1

 Cervical

1

 Prostate

1

 Other

5

Prior treatment regimens

 

 Chemotherapy

 

1

6

2

9

3

7

3+

1

 Prior hormone therapy

1

 Prior radiation

8

No. of cycles of seliciclib administered

42

 Median per patient

2

 Range

(1–6)